New schizophrenia drug enters final testing phase
NCT ID NCT07363577
Summary
This study is testing whether a new medication called LB-102 can help control symptoms during acute schizophrenia episodes. Researchers will compare two different doses of LB-102 against a placebo in 456 adults currently experiencing symptom worsening. The main goal is to see if LB-102 reduces schizophrenia symptoms more effectively than placebo over 6 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.